In an extensive meta-analysis conducted by Lu et al., which included eight large trials involving 16,640 patients with HF, SGLT-2 inhibitors were found to significantly decrease the risk of cardiovascular disease and hospitalization for heart failure (CVD/HHF) by 23% across a diverse range of heart failure patients [11]. The gene discussed is SLC5A2; the disease is hydrops fetalis.